# Ipilimumab and GMCSF Immunotherapy for Prostate Cancer

> **NCT01530984** · PHASE2 · WITHDRAWN · sponsor: **Lawrence Fong**

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** GM-CSF

## Key facts

- **NCT ID:** NCT01530984
- **Lead sponsor:** Lawrence Fong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-06
- **Primary completion:** 2017-12
- **Final completion:** 2018-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Unable to execute contract
- **Last updated:** 2015-10-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01530984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01530984, "Ipilimumab and GMCSF Immunotherapy for Prostate Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01530984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*